Brief: Addex Ends Dipraglurant Phase 2B/3 Study Due To Slow Recruitment Rate
17/06/2022 06:05
June 17 (Reuters) - ADDEX THERAPEUTICS LTD ADXN.S :
* TERMINATES DIPRAGLURANT PHASE 2B/3 STUDY IN PATIENTS WITH
DYSKINESIA ASSOCIATED WITH PARKINSON’S DISEASE DUE TO SLOW
RECRUITMENT RATE
* THIS HAS BEEN ATTRIBUTED TO CONSEQUENCES OF COVID-19
RELATED
PATIENT CONCERNS ABOUT PARTICIPATION IN CLINICAL STUDIES AS WELL
AS STAFFING SHORTAGES AND TURNOVER WITHIN STUDY SITES
* COMPANY IS SUSPENDING COMPANY'S FINANCIAL GUIDANCE
Source text for Eikon: ID:nGNEK4NwT
Further company coverage: ADXN.S
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))